Zelnecirnon

IDEAYA Biosciences advances multiple oncology programs, with over 230 patients enrolled in potential registration-enabling trial for darovasertib in metastatic uveal melanoma, targeting key readouts by end of 2025.

RAPT Therapeutics has commenced a Phase 2a clinical trial to assess RPT193, an oral, once-daily monotherapy, for treating moderate-to-severe asthma.

A new Phase 2 clinical trial is evaluating RPT193, a novel therapeutic candidate for moderate-to-severe atopic dermatitis in adults. The randomized, placebo-controlled study aims to assess both the efficacy and safety profile of this potential treatment option for a condition that affects millions globally.

RAPT Therapeutics halts the development of zelnecirnon (RPT193) after receiving feedback from the FDA regarding safety concerns.

RAPT Therapeutics halts the development of zelnecirnon (RPT193) for inflammatory disorders following unfavorable feedback from the FDA after a clinical hold.